<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743310</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2020-09-Yu-BBIST001</org_study_id>
    <nct_id>NCT04743310</nct_id>
  </id_info>
  <brief_title>Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System</brief_title>
  <official_title>A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blaze Bioscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the use of tozuleristide and the Canvas imaging&#xD;
      system during surgical resection of primary central nervous system tumors, to identify which&#xD;
      tumor types demonstrate detectable fluorescence following administration of 24 mg&#xD;
      tozuleristide and imaged with the Canvas imaging system during surgical resection, and, among&#xD;
      tumors that demonstrate fluorescence, to estimate the true positive rate and true negative&#xD;
      rate of fluorescence in tissue biopsies, as well as sensitivity and specificity of&#xD;
      tozuleristide fluorescence for distinguishing tumor from non-tumoral tissue. The secondary&#xD;
      objectives of the study include evaluating the safety of tozuleristide and the Canvas imaging&#xD;
      system, and to determine if the presence of residual fluorescence at the time of surgery&#xD;
      corresponds to residual tumor evident on post-operative MRI images, or if the absence of&#xD;
      fluorescence corresponds to evidence of no gross residual tumor on post-operative magnetic&#xD;
      resonance imaging (MRI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with fluorescence-positive primary tumor biopsy</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>True positive rate of fluorescence, defined as the percentage of tumor-positive and fluorescence-positive tissue biopsies among all tumor-positive tissue biopsies</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>True negative rate of fluorescence, defined as the percentage of tumor-negative and fluorescence-negative tissue biopsies among all tumor-negative tissue biopsies</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of fluorescence, defined as the percentage of tumor-positive and fluorescence-positive tissue biopsies among all fluorescence-positive tissue biopsies</measure>
    <time_frame>At the time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of fluorescence, defined as the percentage of tumor-negative and fluorescence-negative tissue biopsies among all fluorescence-negative tissue biopsies</measure>
    <time_frame>At the time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of residual tumor measured on post-operative magnetic resonance imaging scans among all patients with evidence of residual fluorescence at the time of surgery</measure>
    <time_frame>At the time of surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From the time of study drug administration 1-24 hours prior to surgery, until 30 days after surgery or until receiving additional therapy for the central nervous system tumor, whichever comes first</time_frame>
    <description>Recorded and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Central Nervous System Tumor</condition>
  <arm_group>
    <arm_group_label>Tozuleristide with Canvas imaging system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tozuleristide</intervention_name>
    <description>tozuleristide 24mg administered intravenously 1-24 hours prior to surgery</description>
    <arm_group_label>Tozuleristide with Canvas imaging system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Canvas imaging system</intervention_name>
    <description>imaging device attached to surgical microscope</description>
    <arm_group_label>Tozuleristide with Canvas imaging system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection of tumor</intervention_name>
    <description>Standard of care surgical resection of tumor</description>
    <arm_group_label>Tozuleristide with Canvas imaging system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MRI obtained within 30 days of study enrollment documents a measurable lesion&#xD;
             consistent with a primary malignant central nervous system tumor for which maximal&#xD;
             safe resection is indicated&#xD;
&#xD;
          -  Adequate renal and liver function&#xD;
&#xD;
          -  Subjects with prior therapy are eligible provided they have recovered from any acute&#xD;
             toxic effects of prior therapy and have sufficient time interval prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, breast-feeding, or planning to conceive a child within 30 days&#xD;
&#xD;
          -  Ongoing serious medical conditions such that participation in the study could put the&#xD;
             subject at increased risk of worsening their condition&#xD;
&#xD;
          -  Subjects planned to undergo only a diagnostic biopsy procedure, without intent to&#xD;
             resect tissue for therapeutic purposes&#xD;
&#xD;
          -  Subjects for whom radiographic evidence suggests a non-intra-axial primary brain tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Kearns</last_name>
    <phone>3109670692</phone>
    <email>Karen.Kearns@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen Kearns, MS</last_name>
      <phone>310-967-0692</phone>
      <email>Karen.Kearns@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Ray Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chirag Patil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Rudnick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jethro Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Surasak Phuphanich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serguei Bannykh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Prasad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>John Yu</investigator_full_name>
    <investigator_title>Director, Surgical Neuro-Oncology</investigator_title>
  </responsible_party>
  <keyword>neurosurgery</keyword>
  <keyword>brain tumor</keyword>
  <keyword>spinal cord tumor</keyword>
  <keyword>surgical resection</keyword>
  <keyword>glioma</keyword>
  <keyword>astrocytoma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>ependymoma</keyword>
  <keyword>medulloblastoma</keyword>
  <keyword>pineocytoma</keyword>
  <keyword>meningioma</keyword>
  <keyword>germ cell tumor</keyword>
  <keyword>craniopharyngioma</keyword>
  <keyword>oligoastrocytoma</keyword>
  <keyword>pineoblastoma</keyword>
  <keyword>extent of resection</keyword>
  <keyword>maximal safe resection</keyword>
  <keyword>neuropathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

